TCR cell therapies continue to gain traction in solid tumors with early Phase II readout from Adaptimmune 

Adaptimmune’s initial pivotal readout for its MAGEA4-targeted TCR cell therapy adds to a trickle of positive data for cell therapies in solid tumors, where immunosuppressive microenvironments and a dearth of tumor-specific targets have been major barriers. 

In an abstract released ahead of the American Society of Clinical Oncology (ASCO) meeting, Adaptimmune Therapeutics plc (NASDAQ:ADAP) reported afamitresgene autoleucel (afami-cel) led to a 41% objective response rate, with 12 responses among 29 synovial sarcoma patients, in the Phase II SPEARHEAD-1 trial. Detailed data will be presented at ASCO on June 4 for the therapy, which comprises autologous T cell genetically modified to express TCRs against MAGEA4...